about
Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysisThe role of fatty acid binding proteins in metabolic syndrome and atherosclerosisClinical use and pharmacological properties of selective COX-2 inhibitors.Genomic medicine: genetic variation and its impact on the future of health care.The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in ScotlandCOX-2 inhibitors and the heart: are all coxibs the same?Selectivity of NSAIDs for COX-2 and cardiovascular outcomeRisk of cardiovascular events and celecoxib: a systematic review and meta-analysis.FDA chief resigns without warning.
P2860
Q28200524-30B0FD39-67CD-4111-99FC-829EF14FDC46Q28271189-3A60215B-C3A6-4161-AB87-DCB3934D8FAAQ34713083-76C8E8E3-A972-48D2-9BEF-B5B36080A74CQ35038039-DB86A2E9-5426-4D05-8DCC-ACBBD73AB7D1Q35827761-86E34760-C3FE-4DA7-907A-D60C61E3DBFFQ36441763-879888B1-853F-4EA7-B3D4-26824C8E7A86Q36536679-F4817A28-CDCC-40F5-93DD-77BD65D367C0Q54920356-6BF421DD-57A4-4B85-98E5-9A955089023BQ55406021-2B9F1C34-22DE-440F-A855-DA6623666576
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
COX-2 selective inhibitors--important lessons learned.
@en
COX-2 selective inhibitors--important lessons learned.
@nl
type
label
COX-2 selective inhibitors--important lessons learned.
@en
COX-2 selective inhibitors--important lessons learned.
@nl
prefLabel
COX-2 selective inhibitors--important lessons learned.
@en
COX-2 selective inhibitors--important lessons learned.
@nl
P1433
P1476
COX-2 selective inhibitors--important lessons learned.
@en
P2093
David J Webb
Simon R J Maxwell
P304
P356
10.1016/S0140-6736(05)17876-3
P407
P577
2005-02-01T00:00:00Z